Use of sulfonamide inhibitors of BCL-2 and BCL-xL to treat ophthalmic disease by selectively removing senescent cells

A method of treating an ophthalmic disease or disorder in a subject who does not have cancer,

• the method comprising administering intraocularly into an eye of the subject that is affected with the disease or disorder an effective amount of the following compound, or a pharmaceutically acceptable salt thereof

A method of removing senescent cells from an eye of a subject in need thereof,

• wherein the senescent cells are identifiable as p16 positive cells that are not cancer cells,
• the method comprising contacting the senescent cells in the eye with an effective amount of (R)—N-(4-(4-(3-(2-(4-chlorophenyl)-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)phenyl)-4-((4-(4-hydroxypiperidin-1-yl)-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide, or a pharmaceutically acceptable salt thereof.